U.S. Markets closed

Edwards Acquires Harpoon Medical

IRVINE, Calif., Dec. 6, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the acquisition of Harpoon Medical, Inc., a privately held medical technology company pioneering beating-heart repair for degenerative mitral regurgitation (DMR).  Edwards announced a structured upfront investment in Harpoon in 2015, with an exclusive option to acquire the company.

Edwards Lifesciences logo. (PRNewsFoto/Edwards Lifesciences Corporation)

Under the terms of the merger agreement, Edwards paid $100 million in cash for Harpoon at closing on Dec. 1.  In addition, there is the potential for up to $150 million in pre-specified milestone-driven payments over the next 10 years.

"We believe the addition of Harpoon Medical's technology and talented team will enable even more opportunities to help patients with degenerative mitral regurgitation," said Bernard Zovighian, Edwards' corporate vice president, surgical heart valve therapy.  "The unique beating-heart repair procedure for mitral valve patients complements Edwards' comprehensive portfolio of treatments for structural heart disease, and reinforces our commitment to innovation in cardiac surgery."

The HARPOON system is designed to facilitate echo-guided repair of mitral valve regurgitation, by stabilizing the prolapsed mitral valve leaflet to restore proper coaptation and valve function.  The HARPOON device is currently investigational and not available for commercial use. It is expected to receive CE Mark approval soon.

"There are a significant number of patients currently undergoing mitral valve surgery that we believe can benefit from Harpoon's therapy during a minimally invasive, beating-heart procedure," said device inventor James S. Gammie, M.D., chairman of the company's scientific advisory board and professor and chief of cardiac surgery at the University of Maryland School of Medicine. "This therapy offers the potential for earlier treatment of degenerative mitral valve disease with faster recovery and less morbidity, while also providing the opportunity for more consistent procedures and outcomes for patients."

Edwards will discuss the HARPOON technology further at its annual Investor Conference on Dec. 7.

Dr. Gammie had an equity interest in Harpoon Medical, and will serve as a consultant to Edwards Lifesciences.

About Edwards Lifesciences

Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements by Mr. Zovighian and Dr. Gammie and statements regarding expected product benefits, future procedural outcomes and timing of CE Mark. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause the roll-out and benefits of the technology to differ materially from those expressed or implied by the forward-looking statements based on a number of factors including but not limited to unexpected outcomes after longer-term clinical experience, or unexpected changes or delays related to regulatory clearance, reimbursement, product manufacturing or clinical practice. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. Our filings, along with important product safety information, are available at www.Edwards.com.

Edwards, Edwards Lifesciences, the stylized E logo, HARPOON, Harpoon Medical, and Harpoon Medical & logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/edwards-acquires-harpoon-medical-300567472.html

  • Pfizer to cut around 2 percent of jobs through early next year
    Business
    Reuters

    Pfizer to cut around 2 percent of jobs through early next year

    U.S. drugmaker Pfizer Inc (PFE.N) plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. Shares of Pfizer were up 1.8 percent at $44.70 in early afternoon trading on the New York Stock Exchange.

  • A former GE exec who trained new managers found that almost all of them were making the same mistake
    Business
    Business Insider

    A former GE exec who trained new managers found that almost all of them were making the same mistake

    Beth Comstock is the former vice chair of General Electric. Comstock would hand out "permission slips" authorizing employees to take risks — but she also said it's important for people to stop hiding behind their excuses. Beth Comstock doesn't tolerate excuses.

  • Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'
    Business
    Yahoo Finance

    Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'

    Billionaire investor and philanthropist Ken Langone, the founder of The Home Depot (HD) and chairman of Invemed Associates, argued that there’s some “big time” structural problems in the market right now. Because if we are on a trajectory of raising rates that means, and if it keeps going that way and I don’t know how high it will go, and it keeps going that way then all the sudden the guy who bought those bonds is going to be looking at a fairly decent loss,” Langone said.

  • Business
    Oilprice.com

    Oil Price Rally Revives Offshore Oil Sector

    The offshore drilling segment of the energy industry was among the hardest hit by the 2014 downturn. Now, according to offshore drilling giant Transocean, it is raking in US$300,000 per day for its specialized vessels deployed in the North Sea. The reason: offshore drilling is as a rule costlier than onshore exploration and production, especially in deep waters.

  • Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For
    Business
    Zacks

    Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For

    Advanced Micro Devices (AMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 24, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Business
    CNBC

    Walmart saves $200 million by changing its light bulbs and $20 million with a new floor wax

    Walmart says switching to LED lights in its parking lots cut its annual energy costs by $200 million. A change in the floor wax it uses cut costs by $20 million a year because the floors need to be buffed less often. It's exactly what Walmart WMT is doing.

  • Legal pot in Canada putting pressure on US
    CGC
    Yahoo Finance Video

    Legal pot in Canada putting pressure on US

    Canada’s moves to legalize recreational marijuana could have major impacts on the US. Yahoo Finance’s Alexis Christoforous speaks with Alexis Keenan about the state of legalization in this country.

  • Business
    CNBC

    Cramer: Alphabet and Amazon, my largest trust holding, can still be bought after Netflix beat

    CNBC's Jim Cramer checks in on FAANG after Netflix's earnings beat to see how shares of the technology giants are holding up. Alphabet and Amazon's stocks look "ripe to buy" after the recent sell-off, the "Mad Money" host says. CNBC's Jim Cramer has spotted some attractive buying opportunities in FAANG — his acronym for the stocks of Facebook FB , Amazon AMZN , Apple AAPL , Netflix NFLX and Google, now Alphabet GOOGL — after the market's latest sell-off.

  • Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade
    Finance
    Market Realist

    Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade

    Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade Credit Suisse’s downgrade Today, CNBC reported that Credit Suisse downgraded Home Depot (HD) stock from “outperform” to “neutral.” Credit Suisse lowered its price target from $222.00 to $204.00

  • Here's the Average Social Security Benefit for 2019
    Business
    Motley Fool

    Here's the Average Social Security Benefit for 2019

    Millions of seniors collect Social Security, and without it, they'd be underwater on their bills. At present, the average retiree gets $1,422 a month in Social Security benefits. There's a world of misinformation surrounding Social Security, and perhaps one of the most detrimental myths out there is the notion that the program is enough to sustain seniors by itself.

  • Sears soars 36% — one day after filing for bankruptcy (SHLD)
    Business
    Business Insider

    Sears soars 36% — one day after filing for bankruptcy (SHLD)

    The retailer received approval on Tuesday to access a $300 million loan to keep it afloat during bankruptcy. Sears Holdings soared as much as 124% — one day after filing for bankruptcy — as the embattled retailer received approval to access a $300 million loan to keep it afloat during bankruptcy.

  • As Canada legalizes marijuana, investors are deciding whether to celebrate too
    CRON
    Yahoo Finance Video

    As Canada legalizes marijuana, investors are deciding whether to celebrate too

    Recreational marijuana is now legal in Canada. What does that mean for investors here in the U.S.? Yahoo Finance's Seana Smith, Adam Shapiro, Andy Serwer and Alexis Keenan weigh in and discuss the long-term opportunities for investment with Marijuana Business Daily's Founder Editor Chris Walsh.

  • Cannabis Stocks Slid ahead of Cannabis Legalization in Canada
    Finance
    Market Realist

    Cannabis Stocks Slid ahead of Cannabis Legalization in Canada

    Cannabis Stocks Slid ahead of Cannabis Legalization in Canada Cannabis stocks slide All of the major cannabis stocks fell the day before recreational cannabis goes on sale in Canada for the first time. The Horizons Marijuana Life Sciences ETF (HMMJ)

  • Business
    CNBC

    Berkshire Hathaway shares look really cheap using Warren Buffett's own method of valuing stocks

    Companies pay investors dividends but they also retain some of their earnings. Over time, companies invest these retained earnings at a higher rate of return and that ultimately boosts their share prices, benefiting their investors. J.P. Morgan analyst Sarah DeWitt calculates that Berkshire's share of undistributed earnings from its stock portfolio is $12 billion, or about $5.19 per Berkshire Class B share.

  • Could Enbridge Inc. Be a Millionaire-Maker Stock?
    Finance
    Motley Fool

    Could Enbridge Inc. Be a Millionaire-Maker Stock?

    Enbridge (NYSE: ENB) has made its investors lots of money over the years. To put that into perspective, if an investor had bought $10,000 worth of Enbridge's stock 20 years ago, it would be worth about $116,000 today assuming they reinvested their dividends. While Enbridge has done an excellent job creating wealth for investors in the past, it faces an uphill battle in making them millionaires in the future.

  • IBM disappoints, more Facebook accusations, Apple apologizes
    Finance
    Yahoo Finance

    IBM disappoints, more Facebook accusations, Apple apologizes

    Here’s a look at some of the companies the Yahoo Finance team will be watching for you today. IBM investors aren’t thrilled with the latest earnings report. The company posted a beat on earnings but revenue missed. CEO Ginni Rometty says the results show

  • Better Buy: The Home Depot, Inc. vs. Lowe's
    Business
    Motley Fool

    Better Buy: The Home Depot, Inc. vs. Lowe's

    Home Depot (NYSE: HD) and Lowe's (NYSE: LOW) have helped countless homeowners increase the value of their homes. They've also made many investors rich. With their shares having soared 879% and 484%, respectively, over the past decade, Home Depot and Lowe

  • Housing Stocks Tumble Midday; Home Depot Dents Dow
    Finance
    Investing.com

    Housing Stocks Tumble Midday; Home Depot Dents Dow

    Investing.com - Home Depot (NYSE:HD) and other housing-leveraged stocks fell in midday trading following disappointing data on home construction. Home Depot fell about 4.2% at 12:08 PM ET (16:08 GMT) and was a drag on the Dow Jones Industrial Average

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Business
    Motley Fool

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson (NYSE: JNJ) recently kicked off earnings season for the healthcare sector, and big pharma investors expecting stagnating sales were pleasantly surprised. Despite a pledge not to raise drug prices earlier this year, pharmaceutical sales kept on climbing, especially among the company's young oncology lineup. Strong uptake of innovative new cancer therapies bodes well for a couple of J&J's peers.

  • AT&T (T) Q3 Earnings Preview: How Are Events Shaping Up?
    Business
    Zacks

    AT&T (T) Q3 Earnings Preview: How Are Events Shaping Up?

    The market expects AT&T (T) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 24.

  • Kinder Morgan (KMI) Tops Q3 Earnings Estimates
    Business
    Zacks

    Kinder Morgan (KMI) Tops Q3 Earnings Estimates

    Kinder Morgan (KMI) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.20 per share. This quarterly report represents an earnings surprise of 5%. Kinder Morgan, which belongs to the Zacks Oil and Gas - Production and Pipelines industry, posted revenues of $3.52 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 3.11%.

  • GE to pay penalty if falls short of French job pledges: ministry
    Business
    Reuters

    GE to pay penalty if falls short of French job pledges: ministry

    General Electric's new CEO told France's finance minister on Wednesday that it would stick to his predecessor's French job pledges or pay a penalty, the Finance Ministry said. Former CEO John Flannery warned French Finance Minister Bruno Le Maire in June that the target was "out of reach", and the government raised the possibility of fines worth 50,000 euros ($57,570) for each job not created. GE's new CEO Larry Culp, who took up his post at the start of the month, told Le Maire in a meeting on Wednesday that France remained a strategic country for the company, the ministry said in statement.

  • Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves
    News
    MarketWatch

    Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves

    After two consecutive off-the-mark quarters, falling short of its own forecasts for subscriber growth, Netflix Inc. hopes to put an end to the big swings in its stock price with some changes to its accounting. Three months ago, Netflix reported weaker-than-expected subscriber growth, sending its stock tumbling about 12% in the next trading day. From last quarter: Is Netflix stock falling down a mountain, or just tripping over a molehill?

  • Kinder Morgan Canada's profit surges on TransMountain sale
    Business
    Reuters

    Kinder Morgan Canada's profit surges on TransMountain sale

    The company said on Wednesday it expects to return about C$1.2 billion ($921.5 million) or C$11.40 per restricted voting share from the sale to its shareholders. Its parent, U.S.-based Kinder Morgan Inc, closed the sale of the controversial Trans Mountain pipeline to the Canadian government for C$4.5 billion in August. Kinder Morgan Canada said net income rose to C$1.35 billion in the three months ended Sept. 30, from C$42.4 million, a year earlier.

  • 10 Marijuana Stocks for the Canadian ‘Pot Rush’
    Finance
    InvestorPlace

    10 Marijuana Stocks for the Canadian ‘Pot Rush’

    After historic legislation that moved Canada as the first G7 member state to legalize recreational marijuana, it became official. This has significant implications, especially for marijuana stocks. As such, investors should strongly consider marijuana stocks to buy, irrespective of their personal reservations.